GSK Doubles Up With Regulus, Signing New Collaboration For HCV Therapeutics

Second collaboration with GSK could bring the microRNA-focused biotech more than $150 million in upfront and milestone payments.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet